How to achieve a near 100% cure rate for H-pylori infection in peptic ulcer patients - A personal viewpoint

被引:57
作者
deBoer, WA
机构
[1] Department of Internal Medicine, Sint Anna Hospital, Oss
[2] Department of Internal Medicine, Sint Anna Ziekenhuis, 5340 BE Oss
关键词
Helicobacter pylori; triple therapy; quadruple therapy;
D O I
10.1097/00004836-199606000-00016
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Infection with Helicobacter pylori is the main etiological factor in duodenal and gastric ulcer disease, and eradication of the organism cures peptic ulcer disease. Cure of the infection therefore has become the ultimate treatment goal in ulcer patients. Only therapies that achieve a >90% cure rate should be used in clinical practice and, as in any other disease, the therapy with the highest cure rates should be used. Bismuth-based triple therapy is considered the gold standard; it has been used successfully in many studies, usually with good tolerability on the part of patients. Many physicians have been hesitant to prescribe this therapy. The regimen is complex, and it is thought to have many side effects. Several groups have shown that concomitant therapy with a proton pump inhibitor increases efficacy and lessens side effects. Moreover, it has become clear that the duration of treatment can be decreased to just 7 days. With this adjustment it now seems sensible to use this short 7-day quadruple therapy, which at present has superior cure rates when compared with any other anti-Helicobacter therapy. This article is a plea for the use of this regimen and gives practical advice about how to employ therapy in general practice. Suggestions are made about how to motivate a patient to comply with the therapy prescribed. If these suggestions are followed, good compliance seems possible, and a near 100% cure rate will be within reach.
引用
收藏
页码:313 / 316
页数:4
相关论文
共 28 条
  • [1] TRIPLE THERAPY ERADICATED HELICOBACTER-PYLORI EQUALLY IN PATIENTS PRETREATED WITH OMEPRAZOLE OR RANITIDINE - A 12-MONTH FOLLOW-UP
    ARCHIMANDRITIS, A
    BALATSOS, V
    DELIS, V
    MENTIS, A
    KASTANAS, K
    SCANDALIS, N
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 1995, 20 (01) : 12 - 16
  • [2] SHORT-TERM LOW-DOSE TRIPLE THERAPY FOR THE ERADICATION OF HELICOBACTER-PYLORI
    BAZZOLI, F
    ZAGARI, RM
    FOSSI, S
    POZZATO, P
    ALAMPI, G
    SIMONI, P
    SOTTILI, S
    RODA, A
    RODA, E
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1994, 6 (09) : 773 - 777
  • [3] BORODY TJ, 1994, AM J GASTROENTEROL, V89, P33
  • [4] OMEPRAZOLE ENHANCES EFFICACY OF TRIPLE THERAPY IN ERADICATING HELICOBACTER-PYLORI
    BORODY, TJ
    ANDREWS, P
    FRACCHIA, G
    BRANDL, S
    SHORTIS, NP
    BAE, H
    [J]. GUT, 1995, 37 (04) : 477 - 481
  • [5] BORODY TJ, 1992, EUR J GASTROEN HEPAT, V4, pS37
  • [6] EFFECT OF ACID SUPPRESSION ON EFFICACY OF TREATMENT FOR HELICOBACTER-PYLORI INFECTION
    DEBOER, W
    DRIESSEN, W
    JANSZ, A
    TYTGAT, G
    [J]. LANCET, 1995, 345 (8953): : 817 - 820
  • [7] DEBOER WA, 1995, AM J GASTROENTEROL, V90, P1381
  • [8] DEBOER WA, 1994, AM J GASTROENTEROL, V89, P1993
  • [9] deBoer WA, 1995, EUR J GASTROEN HEPAT, V7, P1189
  • [10] deBoer WA, 1995, ALIMENT PHARM THER, V9, P633, DOI 10.1111/j.1365-2036.1995.tb00432.x